Navigation Links
Vernalis and Paul Capital Healthcare Sign euro 18.4 Million Financing Agreement
Date:4/20/2008

NEW YORK and WINNERSH, England, April 21 /PRNewswire/ -- Paul Capital Healthcare and Vernalis plc (LSE: VER) today announced that they have signed a financing agreement relating to frovatriptan, Vernalis' product for the treatment of migraine. Under the agreement, Vernalis will receive approximately euro 18.4 million in cash from Paul Capital Healthcare and, in return, Paul Capital Healthcare will receive approximately 90 per cent of Menarini's payments to Vernalis under their exclusive license and supply agreement for the commercialization of frovatriptan in Europe and certain other territories. Vernalis will continue to supply Menarini with frovatriptan active pharmaceutical ingredient.

Frovatriptan is currently approved for the acute treatment of migraine in Europe, the United States, Canada and seven Central American countries.

"Earlier this year, Vernalis restructured its operations to focus on its innovative discovery programs and to advance its promising pipeline of development stage products to the point at which they can be partnered. This transaction with Paul Capital Healthcare secures significant, non-dilutive funds for Vernalis, giving us the platform to rebuild new shareholder value in the medium term," said Tony Weir, CFO, Vernalis.

Dr. Ken Macleod, a partner at Paul Capital Healthcare, said: "Migraine affects about 10 percent of people and leads to billions of dollars in lost productivity each year. After extensively evaluating both the clinical and commercial data for frovatriptan, we believe this drug is positioned to capture a growing share of the market for migraine therapies. Growth capital is the hallmark of the companies and products in which Paul Capital Healthcare invests, and provides a compelling rationale for adding our investment in Vernalis and frovatriptan to our portfolio of investments."

About Paul Capital Partners and Paul Capital Healthcare

Through its funds, Paul Capital Healthcare is one of the largest dedicated healthcare investors globally, with more than $1.4 billion in equity capital commitments and debt facilities under management. Combined, the Paul Capital Healthcare funds have invested more than $925 million in the pharmaceutical, biotechnology, and medical device sectors. These investments are focused on commercial stage companies and products, and consist of investments in the form of royalties, revenue interests, debt and equity. Additional information on Paul Capital Healthcare can be found at http://www.paulcapitalhealthcare.com. Paul Capital Partners manages nearly $5 billion in equity capital commitments for its three investment platforms, which include Paul Capital Healthcare, Private Equity Secondaries and Top Tier Fund-of-Funds. The firm has offices in New York, San Francisco, Paris, London, Hong Kong, and Sao Paolo.

About Vernalis

Vernalis is a specialty bio-pharmaceutical company focused on products marketed to specialist neurologists. The company has two marketed products, Frova(R) and Apokyn(R), and a development pipeline focused on neurology and central nervous system disorders. The company has six products in clinical development and collaborations with leading, global pharmaceutical companies including Novartis, Biogen Idec, Endo, Menarini and Chiesi:

Product Indication Phase Phase Phase Registration Market Marketing

I II III Rights

Apokyn(R) Parkinson's X North

Disease America

Frova(R) Migraine X Menarini

(EU-royalties)

Menstrual Menarini

Frova(R) Migraine X (EU-royalties)

Prevention

V1512 Parkinson's X World Wide

Disease (excl. Italy)

V10153 Thrombotic X World Wide

Disorders

V3381 Neuropathic X World Wide

Pain

V2006 Parkinson's X US

Disease Co-promotion

Biogen Idec

V24343 Obesity X World Wide

AUY922 Cancer X None - royalty

(Novartis)

Contact Information

Vernalis plc Tel: +44 (0) 118 977 3133

Tony Weir, Chief Financial Officer

Brunswick Group (Vernalis inquiries) Tel: +44 (0) 20 7404 5959

Jon Coles

Justine McIllroy

Alex Tweed

Paul Capital Healthcare Tel: +44 (0) 20 7514 0754

Ken Macleod, Partner

Lazar Partners (Paul Capital Healthcare Tel: +1-646-871-8487

inquiries)

Stephanie Seiler Tel: +1-206-713-0124

Email:sseiler@lazarpartners.com


'/>"/>
SOURCE Paul Capital Healthcare
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. SPO Medical Retains American Capital Ventures for Investor Relations Services
2. MichBio Will Host Workshop on Capital Formation Prior to April 22 Annual Meeting
3. CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection
4. Powersafe Technology Corp. Recapitalizes, Executes Merger Agreement with Amplification Technologies, and Invests in Amplification
5. RiverVest Venture Partners(R), a St. Louis-Based Venture Capital Firm Focusing on Life Sciences, Closes on Fund II, Names John P. McKearn, Ph.D., Venture Partner
6. Biotech Avoids Fall Out From Tough Quarter for Capital Markets
7. Plethora and Paul Capital Healthcare sign a $25 million revenue interest financing agreement with an option for an additional $3 million equity investment
8. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
9. Pharmasset Receives $10 Million of Working Capital
10. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
11. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... February 5, 2016 Amarantus BioScience ... company focused on developing products for Regenerative Medicine, Neurology ... Pediatric Disease Designation (RPDD) from the US Food and ... MANF. MANF was previously granted orphan drug designation (ODD) ... Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... training, today announced an interactive FDA compliance training course, Writing ... Affairs Professional Society) accredited interactive course on Morf Playbook—now conveniently available on smartphones ...
(Date:2/4/2016)... RICHMOND, Calif. , Feb. 4, 2016  Sangamo ... therapeutic genome editing, announced today that Edward Lanphier ... an update on the progress of Sangamo,s ZFP Therapeutic ... company,s business strategy at 2:40 pm ET on Thursday, ... Annual Global Healthcare Conference. The conference is being ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... Bloomsburg University’s Digital Forensics Club, takes place February 5-6 at the University’s ... 20+ speakers and activities such as workshops and competitions for ample networking, ...
Breaking Biology Technology:
(Date:2/2/2016)... Checkpoint Inhibitors for Cancer – Explore ... you interested in the future of cancer drugs? ... Visiongain,s report gives those predictions to 2026 at ... Avoid falling behind in data or losing ... those emerging cancer therapies can achieve. There you ...
(Date:2/2/2016)... 2016   Parabon NanoLabs (Parabon) announced ... Research Office and the Defense Forensics and Biometrics ... the company,s Snapshot Kinship Inference software ... generally, defense-related DNA forensics.  Although Snapshot is best ... and ancestry from DNA evidence), it also has ...
(Date:2/1/2016)... Canada , February 1, 2016 ... technological advancements to drive global touchfree intuitive gesture control ... --> Rising sales of consumer electronics coupled ... gesture control market size through ... consumer electronics coupled with new technological advancements to drive ...
Breaking Biology News(10 mins):